Scholarlink

<p>NSCLC remains a leading cause of cancer-related mortality, with limited biomarkers to guide surgical and immunotherapeutic intervention. This study leveraged two complementary plasma proteomics platforms, SomaScan (7596 proteins) and NULISA (250 inflammation-related proteins) to profile 87 timepoints from 56 NSCLC patients, collected pre- and post-surgery and pre- and post-ICI therapy. Robust biomarker selection used adaptive Lasso regression and the Stabl algorithm, with inter- and intra-cohort validation via orthogonal nELISA proteomics. Twenty-one differentially detectable plasma proteins were identified across treatment contexts. Surgical resection induced measurable proteomic changes: non-recurrent patients had higher circulating MUC16 and lower IL36G post-surgery, while recurrent patients showed elevated COX7A2L, FGF19, and SPOCK2, alongside lower FCER2, FCRLA, and SLITRK2. Among ICI-treated patients, responders had lower baseline levels of IL-6, CCL19, IL-2RA, CD200R1, CRP, LIF, PDCD1, CCL7, and SPP1, implicating systemic inflammation and immune regulation in treatment sensitivity. CEACAM5, PTX3, FGF23, and AREG were elevated in patients with worse clinical outcomes and poorer overall survival. MUC16, IL36G, CCL19, and IL-6 were independently validated by nELISA. Cross-platform comparison highlighted the complementary strengths of SomaScan’s broad proteomic coverage and NULISA’s sensitivity for low-abundance proteins. This integrated approach reveals distinct plasma signatures associated with surgical recurrence, ICI response, and prognosis in NSCLC.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dissecting non-small cell lung cancer (NSCLC) with blood proteomics—from surgical to immunotherapeutic responses

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Vahid Yaghoubi Naei,
  • Aaron Kilgallon,
  • Gwendoline Mendes,
  • Akila Wijerathna-Yapa,
  • Sanjay Dutta,
  • Clara Lawler,
  • Connor O’Leary,
  • William Mullally,
  • James Monkman,
  • James Mansfield,
  • Julien Hedou,
  • Mark N. Adams,
  • Ken O’Byrne,
  • Majid E. Warkiani,
  • Arutha Kulasinghe

摘要

NSCLC remains a leading cause of cancer-related mortality, with limited biomarkers to guide surgical and immunotherapeutic intervention. This study leveraged two complementary plasma proteomics platforms, SomaScan (7596 proteins) and NULISA (250 inflammation-related proteins) to profile 87 timepoints from 56 NSCLC patients, collected pre- and post-surgery and pre- and post-ICI therapy. Robust biomarker selection used adaptive Lasso regression and the Stabl algorithm, with inter- and intra-cohort validation via orthogonal nELISA proteomics. Twenty-one differentially detectable plasma proteins were identified across treatment contexts. Surgical resection induced measurable proteomic changes: non-recurrent patients had higher circulating MUC16 and lower IL36G post-surgery, while recurrent patients showed elevated COX7A2L, FGF19, and SPOCK2, alongside lower FCER2, FCRLA, and SLITRK2. Among ICI-treated patients, responders had lower baseline levels of IL-6, CCL19, IL-2RA, CD200R1, CRP, LIF, PDCD1, CCL7, and SPP1, implicating systemic inflammation and immune regulation in treatment sensitivity. CEACAM5, PTX3, FGF23, and AREG were elevated in patients with worse clinical outcomes and poorer overall survival. MUC16, IL36G, CCL19, and IL-6 were independently validated by nELISA. Cross-platform comparison highlighted the complementary strengths of SomaScan’s broad proteomic coverage and NULISA’s sensitivity for low-abundance proteins. This integrated approach reveals distinct plasma signatures associated with surgical recurrence, ICI response, and prognosis in NSCLC.